ClinicalTrials.gg
RecruitingNCT07316452Updated Jan 5, 2026

Risk Prediction of Disease Progression in Early-Onset Coronary Atherosclerosis

An observational study in Coronary Disease and Young Adult, sponsored by Fu Wai Hospital, Beijing, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Fu Wai Hospital, Beijing, China · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 224 studies in Coronary Disease with a site in China — 68 open to participants now, 78 under way, 3 of them phase 3. Coronary Disease · China.

Planned enrollment
15th of 82
10,000 · median 1,508
Started
2025
with 19 others
Observational
82 of 224
30 open now
Primary completion
2027-09
later than 59 of 77 live
Registered
204th of 224
by date

Among the 224 studies in Coronary Disease with a site in China, this one is the 15th largest by planned enrollment of the 82 observational ones that give a count, is one of 20 that started in 2025, is one of 82 observational ones, reaches primary completion later than 59 of the 77 other live ones, and was the 204th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

68 of the 224 studies in Coronary Disease with a site in China are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Coronary Disease with a site in China, or all of them as a file.
02

Study summary

This study is part of a nationwide research project in China that aims to better understand how coronary artery disease develops and progresses in young adults. The study will enroll approximately 10,000 participants aged 45 years or younger who undergo coronary CT scans at multiple hospitals across China.

Information collected at enrollment includes basic health information, cardiovascular risk factors, blood test results, medication use, lifestyle habits, and, for some participants, genetic data. Participants will undergo follow-up coronary CT scans after several years to evaluate changes in coronary artery plaque and disease progression.

By analyzing these clinical and imaging data, the study aims to identify factors associated with disease progression and to develop prediction models that may help estimate an individual's future risk of coronary plaque progression and cardiovascular events. The results of this study may contribute to improved risk assessment and early prevention strategies for coronary artery disease in young populations.

03

Conditions studied

  • Coronary Disease
  • Young Adult

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adults aged 18 to 45 years with symptoms suggestive of coronary artery disease who undergo coronary computed tomography (CT) in participating centers across China. Participants are prospectively and consecutively enrolled into a nationwide observational registry after providing written informed consent and are followed longitudinally for disease progression.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 45 years at the time of enrollment.
  2. Presence of symptoms suggestive of coronary artery disease and completion of coronary computed tomography (CT) examination.
  3. Ability and willingness to provide written and to participate in follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness to complete follow-up assessments.
  2. Inability to provide written .
  3. History of coronary revascularization, including percutaneous coronary intervention or coronary artery bypass grafting.
  4. Poor-quality coronary computed tomography images that are inadequate for reliable plaque assessment.
  5. Presence of severe systemic disease with limited that may interfere with study follow-up.
  6. Pregnant or breastfeeding women.
  7. Participation in another clinical study that may interfere with the outcomes of this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Progression of Coronary Plaque on Computed Tomography

    Progression of coronary atherosclerotic plaque assessed by comparing baseline and follow-up coronary computed tomography scans.

    Time frame: From baseline to follow-up coronary CT, up to 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.

Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 32 months is below that.

Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 5, 2026
StartActual
Jan 1, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07316452
Lead sponsor
Fu Wai Hospital, Beijing, China
Responsible party
Zhihui Hou (Associate Director, Department of Radiology, Fu Wai Hospital, Beijing, China) — Principal investigator
First posted
Jan 5, 2026
Start date
Jan 1, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Jan 5, 2026

Study contacts

Zhihui Hou, MD, PhD
Contact
konglingyihui@126.com
+86 15011451210

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion